NEW YORK (TheStreet) -- Opko Health (OPK) - Get Report shares are down 5.34% to $13.78 in trading on Monday after the biopharmaceutical company reported its fourth quarter financial results after the closing bell on Friday.

The company reported a net loss of $53 million in the fourth quarter, or a loss of 12 cents per diluted share on revenue of $25.5 million. Analysts on average were expecting the company to report a loss of 7 cents per share on revenue of $24.61 million.

Exclusive Report:Jim Cramer's Best Stocks for 2015

The net loss of 12 cents for the period was eight cents worse than the 4 cents per share the company lost during the same quarter last year despite a 23.2% year over year increase in revenue.

Shares are trading on heavy volume today with the stock set to easily surpass its three month daily trading average of 3.77 million shares.

The stock previously reached a 52 week high of $12.48 in intraday trading on January 31.

TheStreet Ratings team rates OPKO HEALTH INC as a Hold with a ratings score of C-. TheStreet Ratings Team has this to say about their recommendation:

"We rate OPKO HEALTH INC (OPK) a HOLD. The primary factors that have impacted our rating are mixed - some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, weak operating cash flow and feeble growth in the company's earnings per share."

Highlights from the analysis by TheStreet Ratings Team goes as follows:

• You can view the full analysis from the report here: OPK Ratings Report

OPK

data by

YCharts